Migrastatics: an overview of the current scenario and future cancer treatments

• by Irene Olivas-Cano, M. Angeles Juanes

• September 2, 2026

Correction: Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

• by Manas Ranjan Sahu, Venu Akkanapally, Partha Sarathi Dasgupta, Sujit Basu

• September 2, 2026

Cancer Communication in an Era of Fragmented Trust

• by Skyler B. Johnson

• August 31, 2026

Coding for Ocular Tumors

Ocular tumor coding can be challenging because ocular oncology often involves evolving lesions, diagnostic uncertainty, and terminology that does not always translate cleanly into ICD-10-CM codes. Understanding how to distinguish benign, malignant, in situ, and uncertain histologic behavior neoplasms is essential for accurate coding, medical necessity, and audit defensibility.

• by Elizabeth Cifers, MBA, MSW, CHC, CPC

• September 1, 2026

• 4 min